
What smart money is saying about Sanara Medtech
1 fund in our archive has pitched Sanara Medtech, most recently White Brook Capital in March 2026.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Sanara Medtech on record in the archive was reported in Q1 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q1 2026 | 1 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- HoldsWhite Brook CapitalMarch 2026
“Sanara Medtech ($SMTI) continues to be an extremely favorable risk reward.”
Sanara Medtech
Fund coverage · 1 thesis
- White Brook CapitalMarch 2026
Sanara Medtech is a wound care company with distributor-driven adoption and growing clinical evidence, guiding to solid growth with potential acceleration and significant upside under strong leadership.
Read the full thesis
Read every full thesis on Sanara Medtech
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→